PMID- 22871410
OWN - NLM
STAT- MEDLINE
DCOM- 20131216
LR  - 20120808
IS  - 1003-0603 (Print)
IS  - 1003-0603 (Linking)
VI  - 24
IP  - 8
DP  - 2012 Aug
TI  - [Therapeutic effects of unfractionated heparin on lipopolysaccharide-activated 
      matrix metalloproteinase-9 and tissue inhibitors of metalloproteinase-1 in 
      endothelial cells].
PG  - 490-2
AB  - OBJECTIVE: To investigate the expressions of matrix metalloproteinase-9 and 
      tissue inhibitors of metalloproteinase-1 (TIMP-1) in injured endothelial cells 
      induced by lipopolysaccharide (LPS) and the effects of unfractionated heparin 
      (UFH) on the level of expressions. METHODS: The human pulmonary microvascular 
      endothelial cells (HPMECs) were injured by LPS (10 mug/ml). In UFH pretreatment 
      group, the cells were interfered with 0.1 U/ml or 1 U/ml UFH within 15 minutes 
      before stimulus of LPS. In control group, the cells were cultured in equal volume 
      of phosphate buffered saline (PBS). The RNA of the respectively cells were 
      extracted at 2, 6, 12 hours after stimulus, and the expressions of MMP-9 mRNA and 
      TIMP-1 mRNA were detected by real-time quantitative reverse 
      transcription-polymerase chain reaction (qRT-PCR). RESULTS: Compared with control 
      group, the expressions of MMP-9 mRNA and TIMP-1 mRNA were increased after 
      stimulation of LPS, and peaked at 12 hours (MMP-9 mRNA: 4.26+/-0.81 vs. 1.00+/-0.46, 
      TIMP-1 mRNA: 4.93+/-0.08 vs. 1.00+/-0.13, both P<0.05), the change in TIMP-1 was more 
      significant. While as UFH pretreatment could significantly down-regulated the 
      mRNA expressions of MMP-9 and TIMP-1 (UFH 0.1 U/ml group MMP-9 mRNA: 2.74+/-0.30, 
      TIMP-1 mRNA: 2.96+/-0.13; UFH 1 U/ml group MMP-9 mRNA: 3.08+/-0.48, TIMP-1 mRNA: 
      2.93+/-0.27, all P<0.05). There were no significant differences in mRNA expressions 
      between two UFH groups. CONCLUSIONS: The expressions of MMP-9 and TIMP-1 of HPMEC 
      injured by LPS were obviously increased, UFH might attenuate the injury via 
      inhibiting the expressions of MMP-9 and TIMP-1.
FAU - Li, Xu
AU  - Li X
AD  - First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
FAU - Zhang, Xiao-juan
AU  - Zhang XJ
FAU - Ma, Xiao-chun
AU  - Ma XC
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - China
TA  - Zhongguo Wei Zhong Bing Ji Jiu Yi Xue
JT  - Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo 
      weizhongbing jijiuyixue
JID - 9887521
RN  - 0 (Lipopolysaccharides)
RN  - 0 (RNA, Messenger)
RN  - 0 (TIMP1 protein, human)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.4.24.35 (MMP9 protein, human)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Cell Line
MH  - Endothelial Cells/*drug effects/metabolism
MH  - Heparin/*pharmacology
MH  - Humans
MH  - Lipopolysaccharides/adverse effects
MH  - Lung/blood supply
MH  - Matrix Metalloproteinase 9/*metabolism
MH  - RNA, Messenger/genetics
MH  - Tissue Inhibitor of Metalloproteinase-1/*metabolism
EDAT- 2012/08/09 06:00
MHDA- 2013/12/18 06:00
CRDT- 2012/08/09 06:00
PHST- 2012/08/09 06:00 [entrez]
PHST- 2012/08/09 06:00 [pubmed]
PHST- 2013/12/18 06:00 [medline]
PST - ppublish
SO  - Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2012 Aug;24(8):490-2.